查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1526265

笔用针头的世界市场

Pen Needles
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 432 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球笔用针头市场预计将达到 48 亿美元

2023年全球笔用针头市场估计为26亿美元，预计到2030年将达到48亿美元，2023年至2030年复合年增长率为9.2%。标准笔针是本报告分析的细分市场之一，预计复合年增长率为 7.3%，到分析期结束时将达到 26 亿美元。分析期内，安全笔针头领域的复合年增长率预计为 11.9%。

美国市场预计将达8.365亿美元，中国预计复合年增长率为10.3%

预计 2023 年美国笔针市场规模将达 8.365 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达3.817亿美元，2023年至2030年复合年增长率为10.3%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 8.0% 和 8.2%。在欧洲，德国的复合年增长率预计为 8.4%。

全球笔针市场－主要趋势与驱动因素总结

笔针是注射笔中用于注射胰岛素、生长激素和其他治疗药物的重要部件。这些针头设计用于连接笔型装置，并提供一种方便、准确的皮下注射方法。注射笔针头有多种长度和规格，使患者和医疗保健提供者可以根据不同的注射部位和患者需求选择最佳的针头。笔式针头的设计重点是最大限度地减少注射过程中的疼痛和不适，具有超薄壁、细尖和润滑涂层等特点。这使得笔式针头特别适合需要频繁注射的患者，例如需要定期注射胰岛素的糖尿病患者。

技术进步极大地改进了笔针的设计和功能。现代笔针采用先进的製造技术，可提高锋利度并减少穿刺力，从而减轻注射疼痛。带有内置防护罩的更安全笔针等创新技术可防止针刺伤害，提高了患者和医护人员的安全。此外，更短、更细的针头的开发消除了对注射的恐惧，使注射更加舒适，并促进更好地坚持治疗方法。高品质材料的使用确保了笔针的耐用性和可靠性，确保您每次使用时都具有一致的性能。这些进步导致笔式针头在各个治疗领域的广泛采用，使其成为药物传递的首选。

笔用针头市场的成长是由多种因素推动的，例如糖尿病盛行率上升、自我给药的日益普及以及针头技术的进步。全球糖尿病患者数量的增加显着增加了对胰岛素输送设备（包括笔针）的需求。由于患者方便和定期治疗的需要，自我给药的趋势进一步推动了市场的成长。技术进步，例如安全针头和超细笔针的开发，使注射变得更安全、更舒适，从而促进了患者的广泛采用。此外，各种长度和规格的笔针提供了更个人化的治疗选择，以满足患者的不同需求。促进糖尿病管理和先进药物输送系统使用的政府措施和医疗保健政策也促进了笔针市场的成长。

受访企业举例（共63家）

  • Advin Health Care
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Cipla Ltd.
  • ARKRAY, Inc.
  • Gerresheimer AG
  • A. Menarini Diagnostics Srl
  • Exelint International Co.
  • Hindustan Syringes & Medical Devices Ltd.
  • Allison Medical, Inc.
  • HTL-Strefa SA
  • GlucoRx Ltd.
  • Cambridge Sensors Ltd.
  • Igaku Needles Private Limited
  • AdvaCare Pharma

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 世界品牌
  • 主要企业
  • 市场趋势和驱动因素
  • 宏观成长的驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP22487

Global Pen Needles Market to Reach US$4.8 Billion by 2030

The global market for Pen Needles estimated at US$2.6 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Standard Pen Needles, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Safety Pen Needles segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$836.5 Million While China is Forecast to Grow at 10.3% CAGR

The Pen Needles market in the U.S. is estimated at US$836.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$381.7 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Pen Needles Market - Key Trends & Drivers Summarized

Pen needles are essential components used with injection pens to deliver medications such as insulin, growth hormones, and other therapeutic agents. These needles are designed to be attached to the pen device, providing a convenient and precise method for administering subcutaneous injections. Pen needles come in various lengths and gauges, allowing patients and healthcare providers to select the most appropriate needle for different injection sites and patient needs. The design of pen needles focuses on minimizing pain and discomfort during injections, with features such as ultra-thin walls, fine tips, and lubricated coatings. This makes pen needles particularly suitable for patients requiring frequent injections, such as those with diabetes who need regular insulin administration.

Technological advancements have led to significant improvements in the design and functionality of pen needles. Modern pen needles incorporate advanced manufacturing techniques that enhance sharpness and reduce penetration force, resulting in less painful injections. Innovations such as safety pen needles, which feature built-in shields to prevent needlestick injuries, have improved safety for both patients and healthcare providers. Additionally, the development of shorter and finer needles has made injections less intimidating and more comfortable, encouraging better adherence to treatment regimens. The use of high-quality materials ensures the durability and reliability of pen needles, providing consistent performance with each use. These advancements have expanded the adoption of pen needles across various therapeutic areas, making them a preferred choice for medication delivery.

The growth in the pen needles market is driven by several factors, including the rising prevalence of diabetes, increasing adoption of self-administration of medications, and advancements in needle technology. The global increase in diabetes cases has significantly boosted the demand for insulin delivery devices, including pen needles. The trend towards self-administration of medications, driven by patient convenience and the need for regular therapy, has further fueled market growth. Technological advancements, such as the development of safety and ultra-fine pen needles, have enhanced the safety and comfort of injections, encouraging broader adoption among patients. Additionally, the increasing availability of pen needles in various lengths and gauges has provided more options for personalized treatment, catering to diverse patient needs. Government initiatives and healthcare policies promoting diabetes management and the use of advanced drug delivery systems are also contributing to the growth of the pen needles market.

Select Competitors (Total 63 Featured) -

  • Advin Health Care
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Cipla Ltd.
  • ARKRAY, Inc.
  • Gerresheimer AG
  • A. Menarini Diagnostics Srl
  • Exelint International Co.
  • Hindustan Syringes & Medical Devices Ltd.
  • Allison Medical, Inc.
  • HTL-Strefa SA
  • GlucoRx Ltd.
  • Cambridge Sensors Ltd.
  • Igaku Needles Private Limited
  • AdvaCare Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Pen Needles - Global Key Competitors Percentage Market Share in 2024 (E)
    • Pen Needles Competitor Market Share Scenario Worldwide (in %): 2022E
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Needles: A Prelude
    • Types of Needles
    • An Insight into Pen Needles
    • Pen Needles for Insulin Injection
    • Global Market Analysis and Prospects
    • Global Pen Needles Market Set for a Rapid Growth
    • Standard Pen Needles Dominate, Safety Pen Needles to Witness Fastest Growth
    • Emerging Markets: Focal Point for Future Growth
    • Competitive Landscape
    • Top Pen Needle Products
    • Recent Market Activity
  • WORLD BRANDS
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Diabetic Population Continues to Drives Demand for Pen Needles
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030 and 2045
    • World Diabetes Prevalence (2000-2045P)
    • Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2019 and 2045
    • Global Diabetes Mellitus Population Breakdown by Geographic Region: 2019, 2030 and 2045?
    • Diabetes Emerges as One of the Leading Causes of Mortality
    • Diabetes-Related Deaths as % of Total Deaths in Below 60 Years Population by Region: 2023
    • Growing Prevalence of Chronic Diseases Drive the Demand for Pen Needles
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • High Risk of Diabetes in the Fast Expanding Aging Population Benefit Market Expansion
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Pen Needles Gain Traction as Insulin Pens Rise in Popularity for Administering Insulin
    • Smart Insulin Pens: A Growing Area of Interest
    • Increasing Role of Self-Injection Devices in Diabetes Management
    • Needle-Free Alternatives: A Growing Threat
    • Innovative Technologies Revolutionize Pen Needles Market
    • Advancements in Insulin Delivery Methods Drive the Demand for Pen Needles
    • Advancements in Pen Needle Technology
    • Droplet Micron Insulin Needle Represents Innovation in the Diabetes Supply Market
  • MACRO GROWTH DRIVERS
    • Increasing Healthcare Expenditure Aids Pen Drives Market Growth
    • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, 2023
    • Increasing Obesity Levels Underpins Market Growth
    • Average Per Capita Annual Health Expenditure (In US$) due to Obesity
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Rising Demand for Biosimilar Drugs Propel the Market for Pen Needles
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Pen Needles Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Facts & Figures
    • US Pen Needles Market Share (in %) by Company: 2022 & 2030
    • Standard (Type) Market Share Analysis (in %) of Leading Players in the US for 2022 & 2030
    • Safety (Type) Competitor Revenue Share (in %) in the US: 2022 & 2030
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • Market Analytics
    • TABLE 20: USA Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • JAPAN
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • CHINA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • EUROPE
    • Market Facts & Figures
    • European Pen Needles Market: Competitor Market Share Scenario (in %) for 2022 & 2030
    • Standard (Type) Market Share (in %) by Company in Europe: 2022 & 2030
    • Safety (Type) Market Share (in %) of Major Players in Europe: 2022 & 2030
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • Market Analytics
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • FRANCE
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • GERMANY
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • INDIA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
  • AFRICA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030

IV. COMPETITION